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Abstract
Aims/hypothesis In a high-fat-fed rat model of type 2
diabetes we noted increased exocrine duct replication. This
is a predisposing factor for pancreatitis and pancreatic
cancer, both of which are more common in type 2 diabetes.
The aim of the study reported here was to establish if
obesity and/or type 2 diabetes are associated with increased
pancreatic ductal replication in humans.
Methods We obtained pancreas at autopsy from 45 humans,
divided into four groups: lean (BMI <25 kg/m
2); obese
(BMI >27 kg/m
2); non-diabetic; and with type 2 diabetes.
Pancreases were evaluated after immunostaining for the
duct cell marker cytokeratin and Ki67 for replication.
Results We show for the first time that both obesity and
type 2 diabetes in humans are associated with increased
pancreatic ductal replication. Specifically, we report that (1)
replication of pancreatic duct cells is increased tenfold by
obesity, and (2) lean subjects with type 2 diabetes
demonstrate a fourfold increase in replication of pancreatic
duct cells compared with their lean non-diabetic controls.
Conclusions/interpretation Pancreatic duct cell replication
is increased in humans in response to both obesity and type
2 diabetes, potentially providing a mechanism for the
increased risk of pancreatitis and pancreatic cancer in those
with obesity and/or type 2 diabetes.
Keywords DPP-IVinhibitor.GLP-1.Obesity.Pancreatic
cancer.Pancreaticductal.Pancreatitis
Abbreviations
HIP Human islet amyloid polypeptide transgenic
FPG Fasting plasma glucose
GLP-1 Glucagon-like peptide 1
Introduction
The incidence of pancreatitis and pancreatic cancer is
increased with obesity [1, 2]. Although the mechanism
underlying this association is unknown, as the incidence of
several other malignancies is increased with obesity [3], it
has been considered to be a possible consequence of
chronic inflammation. We reported increased pancreatic
duct cell replication in Sprague–Dawley human islet
amyloid polypeptide transgenic (HIP) rats fed a high-fat
diet [4]. HIP rats are a model of type 2 diabetes [5, 6]. In
common with type 2 diabetes, the HIP rat develops diabetes
because of impaired beta cell function and loss of beta
cell mass through endoplasmic-reticulum-stress-induced
apoptosis.
We also noted that pancreatic duct cell replication in the
high-fat-fed HIP rat increased as a function of blood
glucose. While pancreatitis and pancreatic cancer can cause
diabetes, there is some evidence to suggest that the
converse may be true [1, 2]. A possible underlying
mechanism to account for an increased risk of pancreatic
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increased pancreatic duct cell replication. Increased pancre-
atic duct cell replication is a characteristic of both
pancreatitis and pancreatic cancer [7–9].
We sought to address the following hypotheses. First,
that pancreatic duct cell replication is increased in obese vs
lean humans. Second, that pancreatic duct cell replication is
increased in humans with type 2 diabetes compared with
non-diabetic individuals. To address these hypotheses we
examined the frequency of pancreatic duct cell replication
in pancreas obtained at autopsy from lean and obese
humans with or without type 2 diabetes. In addition we
studied pancreas obtained at surgery from nine individuals
who underwent pancreatic surgery for resection of pancre-
atic ductal adenocarcinoma (eight cases) and an intraductal
papillary mucinous neoplasm (one case). The surgical
tissue studied from each case was not from the tumour
itself but from adjacent pancreas. In seven cases the
pancreas was negative for tumour but did show signs of
chronic pancreatitis. In two c a s e st h e r ew a si n v a s i v e
adenocarcinoma in the sample.
Methods
Design and case selection Internal Review Board approval
was obtained from both the Mayo Clinic and UCLA.
Human pancreatic tissue, collected at autopsy, was obtained
from four groups: lean non-diabetic individuals; lean
individuals with type 2 diabetes; obese non-diabetic
individuals; and obese individuals with type 2 diabetes.
Potential cases were first identified by retrospective
analysis of the Mayo Clinic autopsy database. The autopsy
cases are a subgroup of those previously used to investigate
a deficit in beta cells in type 2 diabetes [10]. This study
therefore reflects the population of Minnesota at the time
these patients died, which was predominantly (∼98%) of
northern European origin. To be included, cases were
required to have: (1) had a full autopsy within 24 h of
death; (2) had a general medical examination, including at
least one fasting glucose documented in the year before
death; and (3) pancreatic tissue stored that was of adequate
size and quality. Cases were excluded if: (1) potential
secondary causes of type 1 or type 2 diabetes were present;
(2) patients had been exposed to chronic glucocorticoid
treatment; or (3) pancreatic tissue had undergone autolysis
or showed evidence of pancreatitis. Inclusion in the lean
subgroup required a BMI <25 kg/m
2, while inclusion in the
obese subgroup required a BMI>27 kg/m
2. Cases were
further classified as non-diabetic (fasting plasma glucose
[FPG]<6.1 mmol/l) or with diabetes (FPG>7 mmol/l).
Type 2 diabetes vs other forms of diabetes was evaluated
based on the clinical diagnosis of the patient attending the
Mayo Clinic. The clinical diagnosis was further supported
by pancreas pathology (absence of immune infiltrate,
presence of islet amyloid). Pancreatic sections from 45
cases (nine lean non-diabetic individuals, 12 lean type 2
diabetic individuals, 11 obese non-diabetic individuals and
13 obese type 2 diabetic individuals) were ultimately
included in the study (Table 1). Our interest in pancreatic
ductal replication in obesity and type 2 diabetes was
because of the potential role chronically increased pancre-
atic ductal replication may play in the increased risk of
pancreatitis and pancreatic cancer in those conditions. For
the purposes of comparison we therefore also evaluated
ductal replication in nine pancreas samples obtained at
surgical resection for pancreatic adenocarcinoma (eight
cases) and intraductal papillary mucinous neoplasm (one
case). In seven of these cases, the pancreas had no tumour
present but all had features of low-grade pancreatitis. In two
of the cases the sample of pancreas available contained
tumour and the results are reported separately (Table 2).
Case characteristics The lean non-diabetic and lean type 2
diabetic groups were matched for age (80.1±3.5 vs 79.3±
2.2 years) and BMI (22.5±0.7 vs 22.2±0.6 kg/m
2). The
obese non-diabetic and obese type 2 diabetes groups were
also matched for age (61.5±4.9 vs 62.5±3.7 years) and
BMI (35.3±2.3 vs 39.6±1.9 kg/m
2). The lean non-diabetic
and obese non-diabetic cases had similar blood glucose
values (5.5±0.1 vs 5.4±0.1 mmol/l) while the lean and
obese cases with type 2 diabetes, by definition, had higher
values (12.4±0.7 vs 10.2±0.9 mmol/l). The treatments of
the individuals with type 2 diabetes ranged from diet alone
to oral therapy (sulfonylureas) or insulin (Table 1).
Pancreatic tissue processing At autopsy, in all cases,
pancreas was resected from the tail and, with a sample of
spleen, fixed in formaldehyde and embedded in paraffin for
subsequent analysis. Sections, 4μm, were cut from the
paraffin blocks and stained for haematoxylin/eosin and
double-stained for Ki67 (anti-human Ki67 monoclonal
antibody MIB-1, 1/25 [Dako, Carpinteria, CA, USA]) and
cytokeratin (monoclonal anti-pancytokeratin, 1/50 [Sigma-
Aldrich, St Louis, MO, USA]) by immunohistochemistry.
Analysis The haematoxylin/eosin-stained sections were ex-
amined to exclude cases with pancreatitis and autolysis, as
per case-selection criteria. Slides double-stained for Ki67, a
marker of replication, and cytokeratin, a marker of ductal
structures, were examined to determine the percentage of
replicating ductal cells. All sections were viewed with an
Olympus CX40 microscope (Olympus America, Melville,
NY, USA) and images were taken using an Olympus
Magnafire SP camera. A mean of 1,243±62 duct cells
(range 652–3,239) were evaluated per case. To be included
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Case Age (years) Sex BMI (kg/m
2) FPG (mmol/l) Treatment Cause of death
Lean non-diabetic
1 78 F 17.6 5.3 – Acute pulmonary embolism
2 86 M 24.5 6.0 – Acute aortic rupture
3 65 M 22.4 5.3 – Oesophageal haemorrhage
4 81 M 24.5 5.3 – Acute myocardial ischaemia
5 81 M 22.6 5.4 – Acute myocardial infarction
6 87 M 24.5 4.9 – Acute myocardial infarction
7 93 F 23.2 5.5 – Ruptured dissecting aortic aneurysm
8 62 F 21.3 5.4 – Acute myocardial ischaemia
9 88 F 22.1 6.4 – Acute pulmonary embolism
Mean 80.1 22.5 5.5
SEM 3.5 0.7 0.2
Lean type 2 diabetes
1 83 M 21.6 12.1 Diet Pulmonary embolism
2 79 M 23.5 16.2 Insulin Acute myocardial infarction
3 69 F 24.8 13.3 Oral Arrhythmia, IHD
4 83 F 20.0 15.2 Oral Adenocarcinoma of breast
5 66 F 22.2 9.9 Oral Acute myocardial ischaemia
6 68 M 18.8 8.8 Diet Heart failure, IHD
7 84 M 23.7 10.9 Oral Arrhythmia, IHD
8 84 M 19.4 10.9 Diet Acute myocardial infarction
9 78 M 22.7 14.9 Diet Septicaemia
10 83 F 22.7 14.9 Diet Bronchopneumonia, respiratory failure
11 85 F 24.6 10.7 Oral Bronchopneumonia, respiratory failure
12 89 F 22.7 10.8 Insulin Acute myocardial infarction
Mean 79.3 22.2 12.4
SEM 2.2 0.6 0.7
Obese non-diabetic
1 59 M 34.8 5.4 – Intra-abdominal haemorrhage, psoas
muscle abscess
2 63 F 32.2 5.2 – Arrhythmia, IHD
3 52 M 35.0 6.0 – Arrhythmia, acute pulmonary oedema, IHD
4 84 F 33.4 5.4 – Arrhythmia, IHD
5 64 M 31.7 5.4 – Myocarditis
6 44 M 56.3 5.4 – Suicide
7 75 F 30.0 5.4 – Ischaemic colitis, IHD
8 71 F 29.4 4.8 – Disseminated coagulopathy
9 82 M 30.3 5.9 – Acute pulmonary embolus
10 50 F 37.8 5.0 – Acute pulmonary embolism
11 32 M 37.7 5.5 – Motor vehicle accident
Mean 61.5 35.3 5.4
SEM 4.9 2.3 0.1
Obese type 2 diabetes
1 65 M 37.7 16.6 Insulin Acute pulmonary embolism
2 64 F 34.7 11.7 Insulin Congestive heart failure, septicaemia
3 43 F 45.6 8.4 Oral Intracerebral haemorrhage
4 43 M 30.8 8.1 None Metastatic osteogenic sarcoma
5 85 F 32.4 7.9 Oral IHD
6 62 M 42.3 11.7 Insulin Arrhythmia, IHD
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identified and analysed. If that number could not be
identified on a single section, a second, non-adjacent section
of pancreas was obtained and stained for analysis. Ducts of
all sizes were included in the evaluation; the majority of
ducts analysed were less than 35 cells in cross section.
Statistical analysis The data are presented as the mean ±
standard error of the mean. The non-paired Student’s t test
was used to address the stated hypotheses.
Results
Duct cell replication Pancreatic duct cell replication was
increased tenfold in non-diabetic obese vs non-diabetic lean
humans (0.34±0.02% vs 0.03±0.02%, p<0.0001), affirm-
ing the hypothesis that pancreatic duct cell replication is
increased in obesity (Fig. 1). The second hypothesis, that
duct cell replication is increased in type 2 diabetes, was
evident in lean cases. In lean individuals, the presence of
type 2 diabetes was associated with a fourfold increase in
duct cell replication (0.15±0.02% vs 0.03±0.02%, p<
0.001). In obese individuals, the presence of type 2 diabetes
was not associated with a significant increase in ductal
replication above that already present in obese non-diabetic
controls (0.43±0.06% vs 0.34±0.02%, p=NS).
Because, on average, obese individuals died at a younger
age than the lean individuals, we undertook a further
subgroup analysis matching age of death between all
groups. Despite the smaller number of cases, the conclu-
sions were unchanged. Ductal replication was still in-
creased in obese vs lean non-diabetic cases (0.34±0.05% vs
Table 1 (continued)
Case Age (years) Sex BMI (kg/m
2) FPG (mmol/l) Treatment Cause of death
7 85 M 34.9 5.4 Oral Arrhythmia, IHD
8 58 F 56.0 13.8 Insulin Acute intracerebral haemorrhage
9 66 F 33.5 7.4 Insulin Acute myocardial ischaemia, pulmonary
embolism
10 71 M 43.9 5.5 Oral Septicaemia
11 59 F 42.6 11.2 Insulin Septicaemia
12 49 F 39.2 12.1 Oral Adult respiratory distress syndrome
13 63 M 41.1 12.7 Oral Acute myocardial infarction
Mean 62.5 39.6 10.2
SEM 3.7 1.9 0.9
IHD, ischaemic heart disease
Case Age (years) Sex BMI (kg/m
2) FPG (mmol/l) Reason for surgery
Pancreatitis and pancreatic cancer (tumour-free sample)
1 56 F 35.5 8.9 Pancreatic adenocarcinoma
2 67 M 23.8 4.3 Pancreatic adenocarcinoma
3 70 F 24.6 4.6 Pancreatic adenocarcinoma
4 67 F 30 5.7 Pancreatic adenocarcinoma
5 69 M 31.9 8.3 Intraductal papillary mucinous
neoplasm
6 71 M 25.4 6.3 Pancreatic adenocarcinoma
7 55 M 27.9 4.5 Pancreatic adenocarcinoma
Mean 65.0 28.4 6.1
SEM 2.5 1.6 0.7
Adenocarcinoma (sample with tumour)
1 64 M 30.3 5.3 Pancreatic adenocarcinoma
2 64 M 20.5 14.9 Pancreatic adenocarcinoma
Mean 64.0 25.4 10.1
SEM 0 4.9 4.8
Table 2 Clinical characteristics
of surgical study subjects
F, female; M, male
24 Diabetologia (2010) 53:21–260.05±0.02%, p<0.001), but was not increased in obese
type 2 diabetic vs obese non-diabetic individuals (0.45±
0.11% vs 0.34±0.05%, p=NS).
When we evaluated tumour-free pancreas samples from
individuals with pancreatic tumours and pancreatitis, the
frequency of ductal replication was increased further,
approximately threefold, compared with the frequency in
obese cases with type 2 diabetes. As expected, the
frequency of replication in malignantly transformed cells
was markedly increased (Fig. 2).
Discussion
We report that pancreatic duct cell replication is increased
in obese humans. Moreover, we report that type 2 diabetes
is associated with an increase in duct cell replication that is
more obvious in lean than in obese individuals.
Although obesity is recognised as a risk factor for
pancreatitis and pancreatic cancer, the mechanisms remain
elusive [1]. To our knowledge, this is the first report
documenting increased pancreatic duct cell replication in
obese and type 2 diabetes patients who do not have
histological evidence of pancreatitis. Increased pancreatic
duct cell replication is considered a risk factor for
pancreatitis and pancreatic cancer [7–9, 11, 12]. We affirm
that exocrine ductal replication is increased in pancreas
obtained from individuals with pancreatitis associated with
pancreatic cancer, and to an even greater extent in
malignantly transformed ductal cells (Fig. 2). A limitation
of the present study is that pancreas samples from the
pancreatic cancer cases were obtained surgically while
samples obtained from the other groups were removed at
autopsy. To the extent that sensitivity for detection of Ki67
differs between pancreas obtained at surgery vs autopsy,
this comparison might be flawed. To limit any effect,
pancreas with autolysis was excluded from both groups.
While the current data provide a potential explanation
for the increased risk of pancreatitis and pancreatic cancer
in obesity and type 2 diabetes, respectively, an obvious
limitation of an autopsy study is that it cannot reveal the
molecular mechanisms to explain why ductal replication is
increased in obesity and type 2 diabetes. Little is known
about the regulation of pancreatic duct cell replication.
Candidates that might regulate pancreatic duct cell replica-
tion include hormones secreted by the gastrointestinal
neuroendocrine system in response to food intake, includ-
ing incretin hormones such as glucagon-like peptide 1
(GLP-1) [13]. While controversial, it has been proposed
that exocrine ducts house progenitor cells that are capable
of transdifferentiation into endocrine cells to form new
islets (so called islet neogenesis) [14]. It is conceivable that
obesity and type 2 diabetes promote increased formation of
cells from pancreatic progenitors. Treatment of rodents with
GLP-1 mimetics or dipeptidyl peptidase-IV inhibitors
results in increased islet cell clusters in relation to
pancreatic ducts, which is often interpreted as evidence of
neogenesis [14].
We observed an increase in pancreatic duct cell replication
in the high-fat-fed HIP rat model of type 2 diabetes
compared with non-diabetic wild-type rats, and duct cell
replication was further increased with treatment with the
dipeptidyl peptidase-IV inhibitor sitagliptin [4]. Of concern,
we also noted ductal metaplasia in three HIP rats treated with
sitagliptin, and pancreatitis in one. These findings led us to
Fig. 1 Percentage of cytokeratin-staining ductal cells positive for
Ki67. LND, lean non-diabetic (n=9); OND, obese non-diabetic (n=
11); LD, lean with type 2 diabetes (n=12); OD, obese with type 2
diabetes (n=13). Data are presented as mean ± SEM. *p<0.0001, lean
non-diabetic vs obese non-diabetic.
†p<0.001, lean diabetic vs obese
diabetic and lean non-diabetic vs lean diabetic
Fig. 2 Percentage of cytokeratin-staining ductal cells positive for Ki67.
LND, lean non-diabetic (n=9); OND, obese non-diabetic (n=11);
LD, Lean with type 2 diabetes (n=12); OD, obese with type 2 diabetes
(n=13); CP, chronic pancreatitis in tissue sample (n=7); AdCa,
adenocarcinoma present in tissue sample (n=2). Data are presented as
mean ± SEM. *p<0.005, lean non-diabetic vs chronic pancreatitis,
obese non-diabetic vs chronic pancreatitis, obese diabetic vs chronic
pancreatitis.
†p<0.001, lean diabetic vs chronic pancreatitis
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and pancreatitis might be an unintended action of GLP-1 to
promote pancreatic duct cell replication. GLP-1 receptors are
present in pancreatic ducts [4].
In the present study we had no pancreas available to
us from humans treated with GLP-1 mimetics or
dipeptidyl peptidase-IV inhibitors as these have become
available only relatively recently. In the future, it will be
important to carefully evaluate the effects of this class of
drugs on the exocrine pancreas in humans. In the present
study, the individuals with type 2 diabetes had been
treated with diet, sulfonylurea or insulin therapy. There
was no discernible difference in duct cell replication
between these treatments.
In summary, we report that both obesity and type 2
diabetes are associated with increased pancreatic duct
cell replication in humans. These data are consistent
with the hypothesis that the increased risk of pancreatitis
and pancreatic cancer in obesity and type 2 diabetes is
driven by chronically increased pancreatic duct cell
replication. It will be of interest to establish the signals
that foster increased pancreatic duct cell replication in
humans. In addition, the present data lend caution to
the use of therapeutic strategies that act to increase
pancreatic duct cell replication. In HIP rats, GLP-1-
based therapy appears to provoke increased pancreatic
duct cell replication.
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